Literature DB >> 12953808

Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders.

Vichai Atichartakarn1, Khanchit Likittanasombat, Suporn Chuncharunee, Pakorn Chandanamattha, Surapon Worapongpaiboon, Pantep Angchaisuksiri, Katcharin Aryurachai.   

Abstract

Our aim was to study the cause and describe the clinical features of pulmonary arterial hypertension (PHT) in splenectomized beta-thalassemia (beta-Thal) patients. Ten splenectomized beta-Thal patients with systolic pulmonary artery (PA) pressure >30 mm Hg were evaluated by echocardiography, right-heart catheterization, and pulmonary angiography. Five of these patients later underwent hemodynamic studies. Echocardiography and pulmonary angiography on the 10 patients showed normal values of left ventricular systolic function and no findings of acute or chronic pulmonary embolism. Hemodynamic evaluation showed very high PA pressures associated with markedly increased pulmonary vascular resistance indices (PVRIs). Hematological evaluation of the 10 patients showed marked anemia, markedly increased numbers of nucleated red blood cells (nRBCs), and serum ferritin. Mean platelet count, plasma beta2 thromboglobulin, and thrombin-antithrombin III complex levels were significantly increased. It was concluded that PHT can be found in splenectomized beta-Thal patients. Features associated with PHT were female sex, hemoglobin E/beta-Thal, status many years postsplenectomy, marked anemia, markedly increased nRBC count, thrombocytosis, and very high serum ferritin levels. PHT was not due to pulmonary emboli. Our findings suggested that severe PHT was due to increased PVRI from thrombotic pulmonary arteriopathy, likely from chronic low-grade hypercoagulability and platelet activation after splenectomy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12953808     DOI: 10.1007/BF02983382

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  45 in total

1.  Red blood cells from patients with sickle cell disease exhibit an increased adherence to cultured endothelium pretreated with tumour necrosis factor (TNF).

Authors:  S Vordermeier; S Singh; J Biggerstaff; P Harrison; H Grech; T C Pearson; D C Dumonde; K A Brown
Journal:  Br J Haematol       Date:  1992-08       Impact factor: 6.998

2.  Thromboembolic events in beta thalassemia major: an Italian multicenter study.

Authors:  C Borgna Pignatti; V Carnelli; V Caruso; F Dore; D De Mattia; A Di Palma; F Di Gregorio; M A Romeo; R Longhi; A Mangiagli; C Melevendi; G Pizzarelli; S Musumeci
Journal:  Acta Haematol       Date:  1998       Impact factor: 2.195

3.  Pulmonary hypertension in patients with thalassemia major.

Authors:  Z D Du; N Roguin; E Milgram; K Saab; A Koren
Journal:  Am Heart J       Date:  1997-09       Impact factor: 4.749

Review 4.  Pathophysiologic implications of membrane phospholipid asymmetry in blood cells.

Authors:  R F Zwaal; A J Schroit
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

5.  Pathophysiology of the thalassemias. The Albion Walter Hewlett Award presentation.

Authors:  S L Schrier
Journal:  West J Med       Date:  1997-08

6.  Pulmonary arterial webs. A new angiographic sign of previous thromboembolism.

Authors:  K L Peterson; H L Fred; J K Alexander
Journal:  N Engl J Med       Date:  1967-07-06       Impact factor: 91.245

7.  The effect of erythroid hyperplasia on iron balance.

Authors:  P Pootrakul; K Kitcharoen; P Yansukon; P Wasi; S Fucharoen; P Charoenlarp; G Brittenham; M J Pippard; C A Finch
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

8.  Cardiac involvement in thalassemia intermedia: a multicenter study.

Authors:  A Aessopos; D Farmakis; M Karagiorga; E Voskaridou; A Loutradi; A Hatziliami; J Joussef; J Rombos; D Loukopoulos
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

9.  Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia.

Authors:  A Aessopos; G Stamatelos; V Skoumas; G Vassilopoulos; M Mantzourani; D Loukopoulos
Journal:  Chest       Date:  1995-01       Impact factor: 9.410

10.  Reticuloendothelial clearance of circulating fibrin in the pathogenesis of the generalized Shwartzman reaction.

Authors:  L LEE
Journal:  J Exp Med       Date:  1962-05-01       Impact factor: 14.307

View more
  31 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Hemolysis-associated pulmonary hypertension in thalassemia.

Authors:  Claudia R Morris; Frans A Kuypers; Gregory J Kato; Lisa Lavrisha; Sandra Larkin; Titi Singer; Elliott P Vichinsky
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

3.  Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

4.  Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

5.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 6.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

7.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

8.  Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia.

Authors:  Khaled M Musallam; Maria Domenica Cappellini; John C Wood; Irene Motta; Giovanna Graziadei; Hani Tamim; Ali T Taher
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

9.  Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.

Authors:  Claudia R Morris; Hae-Young Kim; John Wood; John B Porter; Elizabeth S Klings; Felicia L Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Sylvia T Singer; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Vandana Sachdev; Sandra Larkin; Jung H Suh; Frans A Kuypers; Elliott P Vichinsky
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 10.  Pulmonary hypertension in sickle cell disease: relevance to children.

Authors:  Gregory J Kato; Onyinye C Onyekwere; Mark T Gladwin
Journal:  Pediatr Hematol Oncol       Date:  2007 Apr-May       Impact factor: 1.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.